Anaveon: Biotech startups make clinical progress

Anaveon has obtained approval from the FDA to launch first-in-human clinical trial for its second cancer drug ANV600, Oculis successfully completed the phase 2b clinical trial with licaminlimab, the first dry eye disease medication while MoonLake is entering phase 3 trials. These developments play a crucial role in advancing the startups' drug development strategies and bringing new therapies to patients.